$SMMT news
The latest SMMT stock news: headlines, filings, AI summaries and sentiment for $SMMT, updated around the clock.
- Summit Therapeutics Inc. - 8-K Filing
- Summit Therapeutics Inc. - 10-Q Filing
- Summit Therapeutics Inc. - 8-K Filing
- AstraZeneca Reports Revenue Growth Driven by Oncology Expansion and Restructuring Initiatives
- ESMO Congress Highlights Oncology Breakthroughs Amid Market Volatility and Fed Uncertainty
- AstraZeneca CEO Discusses Summit Therapeutics' Drug as a Potential Game-Changer for Cancer Treatment
- AstraZeneca and Daiichi Sankyo Collaborate with Summit Therapeutics to Evaluate Combination Therapy
- Biggest Stock Movers on Tuesday Include FICO, CCL, SMMT, and NVTS
- Summit Therapeutics and AstraZeneca Announce $2 Billion Equity Investment Agreement
- Summit Therapeutics Inc. - 8-K Filing
- Summit Therapeutics Inc. - 8-K Filing
- Summit Therapeutics' ivonescimab shows 27% lower mortality than Merck's Keytruda in lung cancer trial
- Summit Therapeutics Shares Rise 28% Following Positive Clinical Trial Results for Ivonescimab
- Summit Therapeutics Inc. - 8-K Filing
- Summit Therapeutics' Lung Cancer Drug Shows Survival Benefit
- Summit Therapeutics Reports Stronger Survival Benefits for Lead Cancer Drug in Extended Follow-Up
- Summit Therapeutics Outlines FDA PDUFA Date for Ivonescimab BLA on November 14 and Plans HARMONi-3 PFS in Late 2026
- Summit Therapeutics Warns Cash Reserves May Not Sustain Operations Beyond a Year
- Summit Therapeutics Inc. - 8-K Filing
- Summit Therapeutics Inc. - 10-Q Filing
- Summit Therapeutics Inc. - 8-K Filing
- Summit Therapeutics Shares Drop After Releasing Late-Stage Trial Data for Lung Cancer Drug
- Summit Therapeutics Inc. - 8-K Filing
- Summit Therapeutics Agrees to Sell Antibiotic Ridinilazole to Biossil for Up to $105 Million
- Summit Therapeutics Withdraws $500 Million Stock Offering Due to Unfavorable Market Conditions
- Summit Therapeutics Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC
- Summit Therapeutics Reveals Positive Phase II Trial Data for Ivonescimab
- Summit Therapeutics Inc. - 8-K Filing
- Summit Therapeutics Shares Drop Despite Positive Phase 3 Data on Ivonescimab in NSCLC
- Stocks Making Significant Premarket Moves: Nvidia, Arm, Taylor Morrison and Others
- Summit Therapeutics Inc. - 8-K Filing
- Chinese Biotech Innovation Poses New Risks for U.S.-Listed Companies
- Chinese Biotech Influence Poses Emerging Risk for U.S.-Based Companies
- Experimental Lung Cancer Drug Shows 34% Reduction in Risk of Death in Late-Stage Trial
- H.C. Wainwright Downgrades Summit Therapeutics Amid Merck's Sac-TMT Trial Data